PlumX Metrics
Embed PlumX Metrics

Safety of de-escalation of surgical intervention for atypical ductal hyperplasia on percutaneous biopsy: One size does not fit all

The American Journal of Surgery, ISSN: 0002-9610, Vol: 225, Issue: 1, Page: 21-25
2023
  • 5
    Citations
  • 0
    Usage
  • 6
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    5
    • Citation Indexes
      5
  • Captures
    6
  • Mentions
    1
    • News Mentions
      1
      • News
        1

Most Recent News

Investigators from University of Kansas Health System Report New Data on Hyperplasia (Safety of De-escalation of Surgical Intervention for Atypical Ductal Hyperplasia On Percutaneous Biopsy: One Size Does Not Fit All)

2023 FEB 03 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Medical Devices Daily -- Current study results on HyperplAsia have been published.

Article Description

Oncologic safety of active monitoring (AM) for atypical ductal hyperplasia (ADH) on core-needle biopsy (CNB) is not well defined. We sought to define oncologic outcomes for AM to manage ADH meeting institutional predefined low-risk criteria (LOW). ADH was diagnosed on CNB from 10/2015-03/2020. LOW (pure ADH, size <1 cm, >50% removed by CNB, <3 foci, and no necrosis) patients were offered AM; all others were recommended for surgical excision. Oncologic outcomes were compared for AM and surgery. 111 were included, 21 (19%) meeting LOW. AM occurred in 18 (86%) while 3 elected for excision (with 0% upgrade). Of the 18 LOW in AM, 2 required additional CNB (none at ADH site): 0% were diagnosed with cancer over median 23 month follow-up. There were no missed cancers at ADH site during AM for LOW, confirming the oncologic safety of AM in this select group.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know